Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.

Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A, Barlev NA.

Cell Death Dis. 2018 Sep 4;9(9):897. doi: 10.1038/s41419-018-0918-x.

2.

Effects of mycoplasma infection on the host organism response via p53/NF-κB signaling.

Borchsenius SN, Daks A, Fedorova O, Chernova O, Barlev NA.

J Cell Physiol. 2018 Aug 26. doi: 10.1002/jcp.26781. [Epub ahead of print]

PMID:
30146800
3.

Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.

Fedorova O, Daks A, Petrova V, Petukhov A, Lezina L, Shuvalov O, Davidovich P, Kriger D, Lomert E, Tentler D, Kartsev V, Uyanik B, Tribulovich V, Demidov O, Melino G, Barlev NA.

Cell Cycle. 2018;17(15):1917-1930. doi: 10.1080/15384101.2018.1506664. Epub 2018 Sep 5.

PMID:
30109812
4.

Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Mittenberg AG, Kuzyk VO, Shabelnikov SV, Gorbach DP, Shatrova AN, Fedorova OA, Barlev NA.

Cell Cycle. 2018;17(14):1745-1756. doi: 10.1080/15384101.2018.1496742. Epub 2018 Aug 1.

PMID:
30009671
5.

Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor.

Canfarotta F, Lezina L, Guerreiro A, Czulak J, Petukhov A, Daks A, Smolinska-Kempisty K, Poma A, Piletsky S, Barlev NA.

Nano Lett. 2018 Aug 8;18(8):4641-4646. doi: 10.1021/acs.nanolett.7b03206. Epub 2018 Jul 9.

PMID:
29969563
6.

Ca2+ -depended signaling pathways regulate self-renewal and pluripotency of stem cells.

Ermakov A, Daks A, Fedorova O, Shuvalov O, Barlev NA.

Cell Biol Int. 2018 May 31. doi: 10.1002/cbin.10998. [Epub ahead of print] Review.

PMID:
29851182
7.

TG2 regulates the heat-shock response by the post-translational modification of HSF1.

Rossin F, Villella VR, D'Eletto M, Farrace MG, Esposito S, Ferrari E, Monzani R, Occhigrossi L, Pagliarini V, Sette C, Cozza G, Barlev NA, Falasca L, Fimia GM, Kroemer G, Raia V, Maiuri L, Piacentini M.

EMBO Rep. 2018 Jul;19(7). pii: e45067. doi: 10.15252/embr.201745067. Epub 2018 May 11.

PMID:
29752334
8.

Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.

Piacentini M, Baiocchini A, Del Nonno F, Melino G, Barlev NA, Rossin F, D'Eletto M, Falasca L.

Cell Death Dis. 2018 Feb 15;9(3):257. doi: 10.1038/s41419-018-0292-8.

9.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

10.

BTK blocks the inhibitory effects of MDM2 on p53 activity.

Rada M, Althubiti M, Ekpenyong-Akiba AE, Lee KG, Lam KP, Fedorova O, Barlev NA, Macip S.

Oncotarget. 2017 Nov 20;8(63):106639-106647. doi: 10.18632/oncotarget.22543. eCollection 2017 Dec 5.

11.

Co-expression of RelA/p65 and ACTN4 induces apoptosis in non-small lung carcinoma cells.

Lomert E, Turoverova L, Kriger D, Aksenov ND, Nikotina AD, Petukhov A, Mittenberg AG, Panyushev NV, Khotin M, Volkov K, Barlev NA, Tentler D.

Cell Cycle. 2018;17(5):616-626. doi: 10.1080/15384101.2017.1417709. Epub 2018 Jan 22.

PMID:
29251177
12.

Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.

Grigoreva TA, Novikova DS, Petukhov AV, Gureev MA, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5197-5202. doi: 10.1016/j.bmcl.2017.10.049. Epub 2017 Oct 20.

PMID:
29089230
13.

E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.

Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA.

Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.

14.

One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Vasileva E, Barlev NA.

Oncotarget. 2017 Apr 4;8(14):23955-23977. doi: 10.18632/oncotarget.15053. Review.

15.

TUMOR MICROENVIRONMENT REGULATION BY HYPOXIA-INDICIBLE FACTORS (HIFs), AND p53 FAMILY PROTEINS.

Petrova VS, Barlev NA.

Tsitologiia. 2017;59(4):259-70. Review. English, Russian.

PMID:
30188089
16.

BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.

Althubiti M, Rada M, Samuel J, Escorsa JM, Najeeb H, Lee KG, Lam KP, Jones GD, Barlev NA, Macip S.

Cancer Res. 2016 Sep 15;76(18):5405-14. doi: 10.1158/0008-5472.CAN-16-0690. Epub 2016 Jul 26.

17.

Human EHMT2/G9a activates p53 through methylation-independent mechanism.

Rada M, Vasileva E, Lezina L, Marouco D, Antonov AV, Macip S, Melino G, Barlev NA.

Oncogene. 2017 Feb 16;36(7):922-932. doi: 10.1038/onc.2016.258. Epub 2016 Jul 25.

PMID:
27452519
18.

Extracellular Proteasomes Are Deficient in 19S Subunits as Revealed by iTRAQ Quantitative Proteomics.

Tsimokha AS, Zaykova JJ, Bottrill A, Barlev NA.

J Cell Physiol. 2017 Apr;232(4):842-851. doi: 10.1002/jcp.25492. Epub 2016 Aug 16.

PMID:
27430664
19.

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.

Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON.

Cell Death Dis. 2016 Apr 14;7:e2195. doi: 10.1038/cddis.2016.96.

20.

Regulation of Endoribonuclease Activity of Alpha-Type Proteasome Subunits in Proerythroleukemia K562 Upon Hemin-Induced Differentiation.

Mittenberg AG, Moiseeva TN, Kuzyk VO, Barlev NA.

Protein J. 2016 Feb;35(1):17-23. doi: 10.1007/s10930-015-9642-x.

PMID:
26661102
21.

KMT Set7/9 affects genotoxic stress response via the Mdm2 axis.

Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, Tentler D, Garabadgiu AV, Melino G, Barlev NA.

Oncotarget. 2015 Sep 22;6(28):25843-55. doi: 10.18632/oncotarget.4584.

22.

The 26S proteasome is a multifaceted target for anti-cancer therapies.

Grigoreva TA, Tribulovich VG, Garabadzhiu AV, Melino G, Barlev NA.

Oncotarget. 2015 Sep 22;6(28):24733-49. doi: 10.18632/oncotarget.4619. Review.

23.

Current genome editing tools in gene therapy: new approaches to treat cancer.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Ermakov A, Melino G, Barlev NA.

Curr Gene Ther. 2015;15(5):511-29. Review.

PMID:
26282844
24.

Genome-editing tools for stem cell biology.

Vasileva EA, Shuvalov OU, Garabadgiu AV, Melino G, Barlev NA.

Cell Death Dis. 2015 Jul 23;6:e1831. doi: 10.1038/cddis.2015.167. Review.

25.

[The role of mitochondrial dynamics in cell death].

Orlova DD, Tribulovich VG, Garabadzhiu AV, Barlev NA, Martin S.

Tsitologiia. 2015;57(3):184-91. Review. Russian.

PMID:
26021167
26.

TAp73 transcriptionally represses BNIP3 expression.

Petrova V, Mancini M, Agostini M, Knight RA, Annicchiarico-Petruzzelli M, Barlev NA, Melino G, Amelio I.

Cell Cycle. 2015 Aug 3;14(15):2484-93. doi: 10.1080/15384101.2015.1044178.

27.

Perspective on multi-target antiplatelet therapies: high content phenotypic screening as an unbiased source of novel polypharmacological strategies.

Landré V, Amelio I, Barlev NA, Knight RA, Lisitsa A, Melino G, Antonov AV.

Mini Rev Med Chem. 2015;15(8):622-9. Review.

PMID:
25930110
28.

[CRISPR/Cas system for genome editing in pluripotent stem cells].

Vasil'eva EA, Melino D, Barlev NA.

Tsitologiia. 2015;57(1):19-30. Review. Russian.

PMID:
25872372
29.

AMP-activated protein kinase: structure, function, and role in pathological processes.

Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG.

Biochemistry (Mosc). 2015 Feb;80(2):127-44. doi: 10.1134/S0006297915020017. Review.

PMID:
25756529
30.

[THE USE OF THE COMMERCIAL APPARATUS DUAL GEL MODULE FOR THE TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS].

Evteeva IN, Starkova TY, Artemov AV, Barlev NA.

Tsitologiia. 2015;57(11):838-42. Russian.

PMID:
27012099
31.

[TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].

Daks AA, Petukhov AV, Shuvalov OY, Vasilieva EA, Melino G, Barlev NA, Fedorova OA.

Tsitologiia. 2015;57(12):876-9. Russian.

PMID:
26995965
32.

[NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].

Shuvalov OY, Fedorova OA, Petukhov AV, Daks AA, Vasilieva EA, Grigorieva TA, Ivanov GS, Barlev NA.

Tsitologiia. 2015;57(12):847-54. Review. Russian.

PMID:
26995961
33.

[The use of apoptosis inducers in the therapy of experimental influenza infection and preventing of chronic post-influenza lung damage].

Zarubaev VV, Tribulovich VG, Beliavskaia SV, Barlev NA, Kiselev OI.

Tsitologiia. 2014;56(3):241-7. Russian.

PMID:
25509421
34.

[Design of cell line stable expressing proteasomal subunit PSMD14 fused to the fluorescent protein EGFP and HTBH tag based on HEK293 cells].

Kulichkova VA, Zaĭkova IuIa, Ermolaeva IuB, Vinogradova EV, Huang L, Tomilin AN, Barlev NA, Tsimokha AS.

Tsitologiia. 2014;56(3):218-24. Russian.

PMID:
25509418
35.

[Mass-spectrometric analysis of proteasomal subunits possessing endoribonuclease activity].

Mittenberg AG, Moiseeva TN, Kuzyk VO, Podol'skaia EP, Evteeva IN, Barlev NA.

Tsitologiia. 2014;56(4):300-15. Russian.

PMID:
25509164
36.

Simultaneous EGFP and tag labeling of the β7 subunit for live imaging and affinity purification of functional human proteasomes.

Kulichkova VA, Artamonova TO, Zaykova JJ, Ermolaeva JB, Khodorkovskii MA, Barlev NA, Tomilin AN, Tsimokha AS.

Mol Biotechnol. 2015 Jan;57(1):36-44. doi: 10.1007/s12033-014-9799-0.

PMID:
25164490
37.

KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress.

Lezina L, Aksenova V, Ivanova T, Purmessur N, Antonov AV, Tentler D, Fedorova O, Garabadgiu AV, Talianidis I, Melino G, Barlev NA.

Cell Death Differ. 2014 Dec;21(12):1889-99. doi: 10.1038/cdd.2014.108. Epub 2014 Aug 15.

38.

DNA damage modulates interactions between microRNAs and the 26S proteasome.

Tsimokha AS, Kulichkova VA, Karpova EV, Zaykova JJ, Aksenov ND, Vasilishina AA, Kropotov AV, Antonov A, Barlev NA.

Oncotarget. 2014 Jun 15;5(11):3555-67.

39.

Immunoaffinity purification of the functional 20S proteasome from human cells via transient overexpression of specific proteasome subunits.

Livinskaya VA, Barlev NA, Nikiforov AA.

Protein Expr Purif. 2014 May;97:37-43. doi: 10.1016/j.pep.2014.02.011. Epub 2014 Feb 28.

PMID:
24583181
40.

miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress.

Lezina L, Purmessur N, Antonov AV, Ivanova T, Karpova E, Krishan K, Ivan M, Aksenova V, Tentler D, Garabadgiu AV, Melino G, Barlev NA.

Cell Death Dis. 2013 Dec 12;4:e953. doi: 10.1038/cddis.2013.483.

41.

Lysine-specific modifications of p53: a matter of life and death?

Marouco D, Garabadgiu AV, Melino G, Barlev NA.

Oncotarget. 2013 Oct;4(10):1556-71. Review.

42.

DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity.

Moiseeva TN, Bottrill A, Melino G, Barlev NA.

Oncotarget. 2013 Sep;4(9):1338-48.

43.

Hot and toxic: hyperthermia and anti-mitotic drugs in cancer therapy.

Barlev NA.

Cell Cycle. 2013 Aug 15;12(16):2533. doi: 10.4161/cc.25841. Epub 2013 Jul 30. No abstract available.

44.

[Characterization of the extracellular proteasomes and its interacting proteins by iTRAQ mass spectrometry].

Zaĭkova IuIa, Kulichkova VA, Ermolaeva IuB, Bottrill A, Barlev NA, Tsimokha AS.

Tsitologiia. 2013;55(2):111-22. Russian.

PMID:
23718073
45.

PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome.

Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA.

Oncogene. 2014 Mar 27;33(13):1621-8. doi: 10.1038/onc.2013.119. Epub 2013 May 20.

PMID:
23686313
46.

The 2nd international workshop 'Novel Therapeutic Strategies in Cancer' in St-Petersburg.

Tentler D, Garabadgiu AV, Barlev NA.

Cell Death Dis. 2013 Jan 24;4:e475. doi: 10.1038/cddis.2012.209. No abstract available.

47.

[The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].

Daks AA, Melino D, Barlev NA.

Tsitologiia. 2013;55(10):673-87. Review. Russian.

PMID:
25509121
48.

[Comparative analysis of methods for purification and concentration of 26S proteasomes isolated from rat liver].

Evteeva IN, Starkova TIu, Artemov AV, Zaĭkova IuIa, Barlev NA.

Tsitologiia. 2013;55(12):893-900. Russian.

PMID:
25474909
49.

MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets.

Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO.

Cell Death Differ. 2013 Feb;20(2):367. doi: 10.1038/cdd.2012.137. Epub 2012 Nov 23. No abstract available.

50.

The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity.

Malatesta M, Peschiaroli A, Memmi EM, Zhang J, Antonov A, Green DR, Barlev NA, Garabadgiu AV, Zhou P, Melino G, Bernassola F.

Oncogene. 2013 Sep 26;32(39):4721-6. doi: 10.1038/onc.2012.463. Epub 2012 Oct 22.

PMID:
23085759

Supplemental Content

Loading ...
Support Center